Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast

Management of Ductal Carcinoma in Situ (DCIS) or Pure Micro-invasive (DCIS-MI) Extended Breast, Axillary Node Sentinel Site (GAS) When the Diagnosis is Made by Biopsy and Treatment by Mastectomy Immediately. Descriptive Study

When invasive components are discovered at mastectomy for vacuum-assisted biopsy (VAB)-diagnosed ductal carcinoma in situ (DCIS), the only option available is axillary lymph node dissection (ALND). The aim of this prospective multicenter trial was to determine the benefit of performing upfront sentinel lymph node (SLN) biopsy for these patients.

Inclusion Criteria:

• Older than 18 years.
• Preoperative histological diagnosis obtained by biopsy
• Ductal carcinoma in situ (DCIS) or pure micro-invasive (DCIS-MI)
• Indication of mastectomy
• Patient signed informed consent

Exclusion Criteria:

• Age < 18 years
• Infiltrating ductal carcinoma (TCC) diagnosed on biopsy
• Pure DCIS diagnosed by lumpectomy
• DCIS can take a conservative treatment
• Mastectomy chosen by the patient
• History of breast carcinoma in situ or invasive ipsilateral
• Prior radiotherapy to the ipsilateral breast
• History of axillary lateral homo
• Patient who for reasons psychological, social, family or geographical could not be treated or monitored regularly according to the criteria of the study
• Patient deprived of liberty or under guardianship